4D Molecular Therapeutics (FDMT) News Today → Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad) Free FDMT Stock Alerts $22.72 +0.15 (+0.66%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 7 at 10:16 AM | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday.June 6 at 11:47 AM | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down to $27.284D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down to $27.28June 6 at 7:30 AM | globenewswire.com4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis ConferenceJune 6 at 5:08 AM | marketbeat.comFranklin Resources Inc. Raises Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Franklin Resources Inc. raised its holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 266.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,564 shares of the coJune 5 at 2:41 PM | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Trading 7.5% Higher 4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 7.5%May 30, 2024 | globenewswire.com4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis ConferenceMay 21, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down After Insider Selling4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down on Insider SellingMay 21, 2024 | insidertrades.comScott Bizily Sells 1,750 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) StockMay 20, 2024 | marketbeat.comInsider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells 1,750 Shares of Stock4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $25.45, for a total transaction of $44,537.50. Following the transaction, the insider now directly owns 1,737 shares of the company's stock, valued at approximately $44,206.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.May 17, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.6%4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 3.6%May 15, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.07. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.44 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 26.75%.May 15, 2024 | marketbeat.comHC Wainwright Equities Analysts Boost Earnings Estimates for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Stock analysts at HC Wainwright lifted their Q2 2024 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a research note issued to investors on Monday, May 13th. HC Wainwright analyst M. Caufield now expects tMay 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), AMN Healthcare Services (AMN) and 4D Molecular Therapeutics (FDMT)May 13, 2024 | marketbeat.com4D Molecular Therapeutics' (FDMT) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday.May 11, 2024 | finance.yahoo.com4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)May 11, 2024 | finance.yahoo.comWe're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To GrowMay 10, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income ProjectionsMay 10, 2024 | investorplace.comFDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.com4DMT Reports First Quarter 2024 Financial Results and Operational HighlightsMay 7, 2024 | finance.yahoo.com4DMT to Participate in Upcoming Investor ConferenceMay 3, 2024 | finance.yahoo.comEtsy stock falling on Q1 earnings miss, cites macro headwindsMay 1, 2024 | globenewswire.com4DMT Announces Presentations at ARVO 2024 Annual MeetingApril 29, 2024 | seekingalpha.com4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed EvolutionApril 23, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 2.9%4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 2.9%April 21, 2024 | investing.com4d Molecular Therapeutics exec sells $45k in stockApril 19, 2024 | marketbeat.comVontobel Holding Ltd. Invests $2.89 Million in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Vontobel Holding Ltd. purchased a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 142,510 shares of the company's stock, valued at approximatelyApril 18, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 1,750 Shares4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,750 shares of the company's stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $25.74, for a total value of $45,045.00. Following the sale, the insider now directly owns 1,737 shares in the company, valued at $44,710.38. The transaction was disclosed in a filing with the SEC, which is available at this link.April 17, 2024 | msn.com4D Molecular Therapeutics (FDMT) Price Target Increased by 5.81% to 53.24April 17, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 2.3% 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 2.3%April 15, 2024 | marketbeat.comRoyal Bank of Canada Increases 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $40.00Royal Bank of Canada raised their price objective on shares of 4D Molecular Therapeutics from $35.00 to $40.00 and gave the company an "outperform" rating in a research note on Monday.April 15, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)April 15, 2024 | marketbeat.comShort Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Expands By 9.6%4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 9,320,000 shares, an increase of 9.6% from the March 15th total of 8,500,000 shares. Based on an average trading volume of 1,170,000 shares, the days-to-cover ratio is currently 8.0 days.April 15, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up to $26.354D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up to $26.35April 15, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Now Covered by BarclaysBarclays assumed coverage on 4D Molecular Therapeutics in a research report on Monday. They set an "overweight" rating and a $45.00 target price on the stock.April 15, 2024 | marketbeat.comDekaBank Deutsche Girozentrale Invests $966,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)DekaBank Deutsche Girozentrale purchased a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 46,000 shares of tApril 14, 2024 | marketbeat.comVanguard Group Inc. Trims Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Vanguard Group Inc. cut its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 3.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,902,467 shares of the company's stock after selliApril 12, 2024 | investing.com4D Molecular Therapeutics Inc (FDMT)April 9, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 4.1%4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 4.1%April 4, 2024 | insidertrades.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $259,102.34 in StockApril 4, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 SharesApril 1, 2024 | marketbeat.comBMO Capital Markets Trims 4D Molecular Therapeutics (NASDAQ:FDMT) Target Price to $63.00BMO Capital Markets cut their price target on 4D Molecular Therapeutics from $70.00 to $63.00 and set an "outperform" rating for the company in a research note on Monday.April 1, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 7.5% on Insider Selling4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 7.5% After Insider SellingApril 1, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Raised to $58.00Jefferies Financial Group raised their price objective on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a "buy" rating in a research report on Monday.April 1, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and eight have issued aMarch 31, 2024 | insidertrades.comScott Bizily Sells 5,833 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) StockMarch 29, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company SharesMarch 29, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 5,833 Shares4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 5,833 shares of 4D Molecular Therapeutics stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $35.04, for a total transaction of $204,388.32. Following the transaction, the insider now directly owns 1,737 shares of the company's stock, valued at $60,864.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.March 29, 2024 | markets.businessinsider.comOptimistic Outlook for 4D Molecular Therapeutics Ahead of Regulatory Update on CF Gene Therapy 4D-710March 28, 2024 | globenewswire.com4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic FibrosisMarch 27, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Reaches New 1-Year High at $35.724D Molecular Therapeutics (NASDAQ:FDMT) Reaches New 12-Month High at $35.72 Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Protect Your Bank Account Before It’s Too Late (Ad)For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction … Stop right now and do these 3 things to protect yourself FDMT Media Mentions By Week FDMT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FDMT News Sentiment▼0.640.73▲Average Medical News Sentiment FDMT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FDMT Articles This Week▼62▲FDMT Articles Average Week Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KRYS News CRSP News IBRX News IMVT News SWTX News ACLX News APGE News DNLI News IOVA News IMCR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FDMT) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s...Weiss Ratings | SponsoredMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored